Skip to content

EBITDA margin at other companies

Baxter International logo
Baxter InternationalBAX
5.9%-6.2pp
PTH
Pelthos Therapeutics Inc.PTHS
-145.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
42.4%+19.5pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-89.6%-40.8pp
RFL
Rafael Holdings, Inc.RFL
-3,696.5%+2,055pp
Opko Health logo
Opko HealthOPK
-1.9%-0.9pp

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Calculated from Cumberland Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's EBITDA margin?
Cumberland Pharmaceuticals (CPIX) reported EBITDA margin of -6.7% in Q1 2026.
How has Cumberland Pharmaceuticals's EBITDA margin changed year-over-year?
Cumberland Pharmaceuticals's EBITDA margin decreased by 282.9% year-over-year, from 3.7% to -6.7%.
What is the long-term trend for Cumberland Pharmaceuticals's EBITDA margin?
Over 5 years (2020 to 2025), Cumberland Pharmaceuticals's EBITDA margin has grown at a -7.0% compound annual growth rate (CAGR), from -4.4% to 3%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.